PMID- 19494241 OWN - NLM STAT- MEDLINE DCOM- 20090921 LR - 20211020 IS - 1522-1563 (Electronic) IS - 0363-6143 (Print) IS - 0363-6143 (Linking) VI - 297 IP - 2 DP - 2009 Aug TI - Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. PG - C471-80 LID - 10.1152/ajpcell.00019.2009 [doi] AB - This study was designed to investigate the role of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) in the reabsorption of neovessels in collagen gel cultures of rat and mouse aortic rings. Aortic angiogenesis was associated with collagen lysis and production of the matrix-degrading enzymes MMP-2, MMP-9, and membrane-type MMP (MT1-MMP, or MMP-14). Vascular growth and regression were not affected by disruption of MMP-2 or MMP-9. In addition, no effect on vascular regression was observed by blocking plasmin, a protease implicated in the activation of MMPs, with epsilon-aminocaproic acid or by adding plasminogen, which caused a modest increase in vascular proliferation. Conversely, angiogenesis was blocked and vessels stabilized by inhibiting MT1-MMP with neutralizing antibodies, TIMP-2, TIMP-3, or TIMP-4. TIMP-1, which blocks MMP-2 and MMP-9 but is a poor inhibitor of MT1-MMP, had no antiangiogenic effect. However, TIMP-1 prolonged the survival of neovessels following angiogenesis. Vascular regression was accelerated in aortic cultures from TIMP-1- and TIMP-2-deficient mice. The vascular survival effect of anti-MT1-MMP antibodies and TIMPs with MT1-MMP inhibitory activity was associated with complete inhibition of collagen lysis. In contrast, TIMP-1 had no anticollagenolytic effect. These results indicate that MT1-MMP plays a critical role not only in angiogenesis but also in vascular regression and demonstrate that TIMPs with anti-MT1-MMP activity have opposite effects on angiogenic outcomes depending on the stage of the angiogenic process. This study also suggests the existence of a TIMP-1-mediated alternate pathway of vascular survival that is unrelated to MT1-MMP inhibitory activity. FAU - Aplin, A C AU - Aplin AC AD - Department of Pathology, University of Washington, Seattle, WA, USA. FAU - Zhu, W H AU - Zhu WH FAU - Fogel, E AU - Fogel E FAU - Nicosia, R F AU - Nicosia RF LA - eng GR - HL52585/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20090603 PL - United States TA - Am J Physiol Cell Physiol JT - American journal of physiology. Cell physiology JID - 100901225 RN - 0 (Antifibrinolytic Agents) RN - 0 (Protein Isoforms) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9001-91-6 (Plasminogen) RN - EC 3.4.21.7 (Fibrinolysin) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - EC 3.4.24.80 (Matrix Metalloproteinase 14) RN - U6F3787206 (Aminocaproic Acid) SB - IM MH - Aminocaproic Acid/metabolism MH - Animals MH - Antifibrinolytic Agents/metabolism MH - *Aorta/anatomy & histology/metabolism MH - Fibrinolysin/metabolism MH - Humans MH - Matrix Metalloproteinase 14/*metabolism MH - Matrix Metalloproteinase 2/genetics/metabolism MH - Matrix Metalloproteinase 9/genetics/metabolism MH - Mice MH - *Neovascularization, Physiologic MH - Plasminogen/metabolism MH - Protein Isoforms/genetics/*metabolism MH - Rats MH - Tissue Culture Techniques MH - Tissue Inhibitor of Metalloproteinases/genetics/*metabolism PMC - PMC2724089 EDAT- 2009/06/06 09:00 MHDA- 2009/09/22 06:00 PMCR- 2010/08/01 CRDT- 2009/06/05 09:00 PHST- 2009/06/05 09:00 [entrez] PHST- 2009/06/06 09:00 [pubmed] PHST- 2009/09/22 06:00 [medline] PHST- 2010/08/01 00:00 [pmc-release] AID - 00019.2009 [pii] AID - C-00019-2009 [pii] AID - 10.1152/ajpcell.00019.2009 [doi] PST - ppublish SO - Am J Physiol Cell Physiol. 2009 Aug;297(2):C471-80. doi: 10.1152/ajpcell.00019.2009. Epub 2009 Jun 3.